Form 4: Director Receives RSU Grant from Cue Biopharma

Cue Biopharma reports a restricted stock unit grant to Director Daniel A. Camardo, with vesting over three years.

Summary

• Daniel A. Camardo, a Director at Cue Biopharma, Inc., received a grant of 21,800 restricted stock units (RSUs) on July 9, 2026.
• The RSUs will vest in three equal tranches on July 9, 2027, July 9, 2028, and July 9, 2029.
• Vesting is contingent upon Mr. Camardo's continued service to the company through each respective vesting date.
• This transaction is reported under SEC Form 4, indicating a change in beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation practice for a director rather than a significant financial or strategic development for the company.

Positives

• Director compensation through equity awards like RSUs can align management interests with shareholder value.
• The phased vesting schedule encourages long-term commitment from the director.

Negatives

• No specific financial performance metrics are associated with this RSU grant, making it purely a compensation event.

Risks

• The value of the RSUs is subject to the future performance and stock price of Cue Biopharma.
• Continued service is a condition for vesting, meaning any departure before vesting dates will result in forfeiture of unvested RSUs.

Future Outlook

The future outlook related to this filing is solely tied to the continued service of Daniel A. Camardo and the subsequent vesting of his RSUs over the next three years. The value of these RSUs will fluctuate with the company's stock performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biopharmaceutical industry to attract and retain experienced leadership, especially in companies focused on research and development where long-term vision is crucial.

Stakeholder Impact

• Shareholders: The grant itself does not immediately impact share count but represents future dilution if RSUs are exercised. The long-term alignment of director incentives could positively influence shareholder value.
• Employees: This is a director-specific compensation event and does not directly impact other employees.
• Management: Reinforces standard compensation practices for board members.

Next Steps

• Continued service by Daniel A. Camardo through the specified vesting dates.
• Automatic vesting of RSUs on July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service.

Key Dates

Keywords

Cue Biopharma, CUE, Form 4, Restricted Stock Units, RSU, Director Compensation, Beneficial Ownership, Equity Grant, Vesting Schedule